MET and cancer: Unlike ICB or chemotherapy, these drugs target DNA damage responses or oncogenic signaling pathways preferentially utilized by cancer cells.25,26 Targeting BRAF, EGFR, PDGRA, KIT, PIK3CA, ALK, MET, ROS1, ERBB, CDK12, and others has improved cancer care, however durable responses are uncommon.27,28 Historically, the ability of the FDA-approved kinase inhibitors to interact with the immune system was ignored.